Soft tissue sarcoma is a malignant tumor that occurs in fibrous tissue, adipose tissue, smooth muscle tissue, transverse muscle tissue, nerve tissue, mesothelial tissue, synovial tissue, blood vessels and lymphatic vessels, etc. Its incidence is less than 1% of systemic malignant tumors. It is because of its rare incidence that it is often overlooked. However, soft tissue sarcoma is highly malignant and can cause limb lesions and even directly endanger patients’ lives, and its incidence is on the rise, becoming a malignant tumor that seriously endangers people’s physical and mental health. Soft tissue sarcoma can occur at any age and in all parts of the body, but it is more common in people over 30 years old, and is more common in men than women, especially in the limbs and trunk. Early symptoms of soft tissue sarcoma are painless masses with rapid growth; late or recurrent masses may invade surrounding tissues (such as nerves and blood vessels) and cause pain, swelling and other compression symptoms, resulting in skin rupture and bleeding. Due to the lack of awareness of soft tissue sarcoma, early clinical symptoms are not taken seriously, resulting in 60% of patients being diagnosed in the middle and late stages. As the early symptoms are not obvious, they are often misdiagnosed as injury or arthritis, and 50% of patients are delayed due to failure to receive timely diagnosis and standard treatment, and face the double threat of life-threatening amputation or distant metastasis due to local recurrence after surgery. The first diagnosis and treatment is directly related to whether the patient can retain the function of the limb, and the best time for treatment is the first surgery. The best time for treatment is the first surgery. By adopting a comprehensive individualized treatment plan based on surgery combined with radiotherapy, patients can receive radical treatment with a safe limb preservation rate of over 90%, a 10-year survival rate of about 80%, and a postoperative recurrence rate of less than 10%.